Stem Pharm
Neuroinflammation-Focused Drug Discovery Using Human Organoids
Neuroinflammation-Focused Drug Discovery Using Human Organoids
Stem Pharm is a neurological drug discovery platform company developing the next-generation of neurologic drugs using a human-first approach. Stem Pharm’s proprietary drug discovery platform is based on human 3D neuro-immune organoids that feature microglia and model neuroinflammation, which play a critical role in many neurological diseases. The company applies this platform to discover and validate disease targets and therapeutics for its internal programs in epilepsy, neurodegeneration, and brain cancer as well as for its biopharma partners’ therapeutic programs. Stem Pharm is based in Madison, WI, a hub for innovative stem cell and biosciences research.
There is no investment information
No recent news or press coverage available for Stem Pharm.
We care about your data, and we'd love to use cookies make your experience better.